Clinivate

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clinivate

What is Clinivate? Overview and Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical preparation (Cream or Ointment)
Pharmacological class Corticosteroid (High-Potency)
General purpose Alleviating symptoms of inflammatory skin disorders
Origin Synthetic fluorinated glucocorticoid

What Type of Medicine is Clinivate? (Classification and Origin)

Clinivate is a proprietary name for a topical preparation that is defined by its active ingredient, Betamethasone Dipropionate, a potent, synthetic fluorinated glucocorticoid. This substance belongs to the Corticosteroid pharmacological class. The medicine's classification as a high-potency topical agent dictates its intended role, which is the effective modulation of the inflammatory and immune responses within the skin. The compound's synthetic origin is chemically confirmed by various authoritative bodies, establishing it as a highly reliable agent supported by pharmacological studies for clinical use.


Composition, Form, and General Action

The physical structure of Clinivate is a semisolid dosage form, specifically a cream or an ointment, designed for topical administration. It functions as a single-ingredient product, where the Betamethasone Dipropionate is suspended within a specialized base that ensures efficient local delivery.

As a potent corticosteroid, the general action of Clinivate is to exert a powerful anti-inflammatory effect and localized immunosuppressive action. The compound is clinically recognized for its ability to quickly reduce the swelling, redness, and severe itching known as pruritus, which is characteristic of various dermatoses. This focused effect provides prompt relief from the intense discomfort and helps restore the skin's equilibrium, serving as a rapid, localized intervention for inflammatory issues.

Regulatory References

  1. Betamethasone Dipropionate Ointment, USP 0.05% Product Information
  2. Betamethasone Dipropionate Topical Cream and Ointment - DailyMed
  3. Betamethasone Dipropionate Indications and Usage (Corticosteroid-Responsive Dermatoses)
  4. Betamethasone Dipropionate: Synthetic Adrenocorticosteroid
  5. Betamethasone Dipropionate Topical Ointment - DailyMed
  6. Betamethasone Dipropionate: Synthetic Adrenocorticosteroid Description
  7. Betamethasone Dipropionate Topical Cream and Ointment
  8. Betamethasone Dipropionate Cream USP 0.05% - DailyMed
  9. Betamethasone Dipropionate Ointment USP 0.05% - DailyMed
  10. Betamethasone Dipropionate Ointment - For Dermatologic Use Only
  11. Betamethasone Dipropionate Active Ingredient - DailyMed
  12. Betamethasone Dipropionate Clinical Pharmacology - Anti-Inflammatory Action
  13. Betamethasone Dipropionate Clinical Pharmacology - Immunosuppressive Action
  14. Betamethasone Dipropionate: Relief of Pruritic Manifestations
  15. Corticosteroid-Responsive Dermatoses - FDA Label

What side effects are possible with Clinivate?

The official safety profile for Clinivate primarily documents local and systemic adverse reactions, classified by affected organ system and frequency.

The most commonly reported adverse reactions are local cutaneous effects which include stinging (reported in 0.4% of adult patients), burning, itching, irritation, dryness, and folliculitis. Dermatological effects associated with prolonged use can include skin atrophy (thinning), striae (stretch marks), and changes in pigmentation. In pediatric patients, signs of skin atrophy, telangiectasia, and bruising are reported more commonly (10%).

Serious adverse reactions stem from the potential for the active ingredient to be absorbed into the bloodstream. These systemic effects fall under Endocrine and Metabolic System Disorders, including reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations resembling Cushing’s syndrome. Ophthalmic disorders such as the development of cataracts or glaucoma have also been documented.

Safety statements note that the risk of systemic absorption is augmented by prolonged use, the application to large body surface areas, and the use of occlusive dressings. Pediatric patients are at greater risk for systemic toxicity, HPA axis suppression, and effects on growth due to proportionally larger absorption. The medicine is formally restricted for use in patients with a history of hypersensitivity to its components or in the presence of certain local dermatological infections unless appropriate concomitant anti-infective treatment is also administered.

Overdose and Emergency Response

The overdose profile for Clinivate is defined by the potential for systemic absorption of the potent corticosteroid through the skin, as documented in regulatory information for excessive or prolonged use. This can lead to systemic effects characteristic of glucocorticoid excess, even though there is no specific antidote listed for the resulting systemic toxicity.


Documented Overdose Manifestations

Classification Manifestation/Finding
Primary Endocrine Risk Reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression
Clinical Signs Manifestations of Cushing’s syndrome (rare) and steroid withdrawal (upon cessation)
Metabolic Findings Hyperglycemia (high blood sugar) and Glucosuria (glucose in the urine)

Emergency Actions and Required Monitoring

Overdose effects are generally reversible, but official labeling mandates that patients applying a large dose over a large surface area should be evaluated periodically for evidence of HPA axis suppression. This evaluation is done using the ACTH stimulation test or the Urinary Free Cortisol test. If HPA axis suppression is confirmed, the required action is to modify drug use (e.g., gradual withdrawal or substitution with a less potent steroid).

Urgent medical help is required if signs and symptoms of steroid withdrawal occur, as this condition may necessitate treatment with supplemental systemic corticosteroids. Pediatric patients are identified in regulatory sources as being more susceptible to systemic toxicity and severe outcomes, including intracranial hypertension, due to their body-mass ratio.

Therapeutic Uses of Clinivate

What Clinivate Treats: Main Uses and Benefits

Clinivate is commonly used for symptomatic relief in clinical settings that involve acute or unstable symptom patterns. Its core role in therapeutic management is established for managing inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This medicine provides support that helps ease the overall burden of distressing manifestations associated with several severe, non-infectious skin conditions.


This medicine is applied in conditions characterized by recurrent or episodic manifestations of heightened symptoms, including plaque psoriasis, severe atopic dermatitis (eczema), and lichen planus. It helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that may assist with supporting functional stability. It is often used during phases when symptoms become more noticeable and short-term symptomatic assistance is needed.

Providing Focused Symptom Relief

The primary therapeutic benefit supports improved comfort during periods of heightened symptoms by assisting in addressing pronounced symptoms, especially severe pruritus (itching) and erythema (redness). Clinivate is considered relevant for easing symptoms that interfere with daily comfort when associated with physical changes like skin thickening and excessive scaling. This support contributes to easing the overall symptom load when dense manifestations are temporarily overwhelming.


Quick Fact: Relief for Pruritus
This medication is applied to manage intense itching that often accompanies severe skin inflammation, and may assist in managing the effects of the scratch cycle.

Regulatory References

  1. U.S. National Library of Medicine (DailyMed) prescribing information

Eligibility and Restrictions for Use

Who Can and Cannot Use Clinivate?

Eligibility for Clinivate (Betamethasone Dipropionate) is strictly defined by regulatory authorities and is determined by patient history, age, and specific clinical conditions.

Contraindications and Restrictions

Population Status Regulatory Rule
Absolute Contraindication The medicine is contraindicated in patients with a known hypersensitivity to betamethasone dipropionate, other corticosteroids, or any other component of the preparation.
Condition-Based Exclusion It must not be used on skin areas affected by specific conditions, including rosacea, perioral dermatitis, acne vulgaris, and most viral, fungal, or bacterial infections unless concurrently treated.

Age and Special Population Eligibility

Adults are the primary population for established use. The medicine is not recommended for children 12 years of age and younger due to their increased susceptibility to systemic adverse effects, such as HPA axis suppression.

Use in pregnancy is classified as Category C and is generally permitted only if the potential benefit justifies the potential risk to the fetus. If used while breastfeeding, application to the breast area must be avoided to prevent infant exposure.

Furthermore, use is restricted on sensitive areas such as the face, groin, or axillae (armpits), and application under occlusive dressings (bandages) is generally not permitted.

What should I know about interactions with other medicines?

Clinivate Interactions with other medicines and products

The official regulatory documents for Clinivate (Betamethasone Dipropionate topical) define its interaction profile primarily by the risk of additive systemic exposure to glucocorticoids. This structure highlights constraints concerning concurrent use with other potent agents that may contribute to the body's overall corticosteroid load.


Documented Interaction Patterns

The most significant interaction is Pharmacodynamic, stemming from the concurrent use of other corticosteroid-containing products, whether administered topically or systemically. This combination may increase the total systemic glucocorticoid exposure and elevate the potential for systemic corticosteroid effects, such as reversible HPA axis suppression. No specific drug-drug interactions based on CYP enzyme inhibition or transporter mechanisms are explicitly documented in regulatory labeling.


Interaction-Related Restrictions and Considerations

Category Regulatory Statement
Co-administration Caution Caution is advised against the concurrent use of more than one corticosteroid-containing product to prevent additive systemic exposure.
Timing-Based Rules No mandatory timing separation rules for co-administered medicines are specified.
Hepatic Impairment Liver failure is noted as a risk factor that may predispose a patient to greater systemic absorption and potential effects from the drug.
Pediatric Patients This population is identified as being at a greater risk of systemic toxicity, making any potential for increased systemic exposure a heightened concern.
Food/Supplements No explicit interactions with food, alcohol, or herbal supplements are documented in the official prescribing information.

Mechanism of Action

Intracellular Signaling Shutdown and Receptor Agonism

This mechanism begins when Betamethasone Dipropionate acts as an agonist for the Glucocorticoid Receptor ( GR), which then moves into the cell nucleus. This interaction executes transcriptional modulation, where it actively suppresses the genetic instructions for key pro-inflammatory proteins (like those controlled by NF-kappa B), while simultaneously initiating the synthesis of anti-inflammatory proteins. This core action establishes the molecular basis for the modulation of the localized immune-inflammatory cascade.

Enzyme Cascade Inhibition and Mediator Control

A critical downstream effect of GR activation is the induction of Lipocortin-1, which indirectly blocks the enzyme Phospholipase A2 ( PLA2). By restricting PLA2 activity, the mechanism limits the release of Arachidonic Acid, the necessary precursor for synthesizing mediators such as prostaglandins and leukotrienes. This restriction limits the effect of vasoactive mediators on capillary permeability, influencing fluid dynamics and local tissue volume.

Mechanistic Constraints (Tachyphylaxis)

The effectiveness of this localized action is constrained by a biological limitation: continuous, high-level stimulation can lead to Glucocorticoid Receptor downregulation within the cells. This cellular feedback mechanism, known as tachyphylaxis, physically reduces the number of functional binding sites, thereby constraining the functional activity of the mechanism and its capacity to sustain transcriptional modulation.

Dosage and Administration Information

Instruction Map: How to Use Clinivate — Administration Guidelines

This map formalizes the instructions for the administration of Clinivate (Betamethasone Dipropionate) as established for therapeutic use.


Administration Scope

Instruction Administration Rule
Route of administration Topical (Dermatologic) use only; the product is strictly designated for external use only.
Dosing schedule Apply a thin film of the cream or ointment to the affected skin areas once daily, or in some contexts, a twice daily application may be specified.
Special procedural conditions Total use of high-potency formulations should not exceed 50 g per week.
Age-group administration rules Use in pediatric patients (typically under age 12 or 13) is generally restricted to a maximum treatment duration, such as 5 days, if use is authorized.

Instruction Classifications (High-Level)

Administration method type: Topical (Cream or Ointment).

Frequency pattern: Daily (once or twice per 24 hours).

Use-context constraints: Short-term use only. Application must be discontinued upon achieving control of the condition. Treatment should be re-evaluated if no improvement is observed after a 2-week period. Avoid use with occlusive dressings and on areas such as the face, groin, and axillae.


Connection to the overall use protocol (2–4 sentences): The protocol mandates a topical administration route using a thin film, which standardizes the localized delivery of the medicine. This routine is defined by a once or twice daily frequency and is constrained by a short-term duration to manage the use of this potent formulation. The rules regarding application limits and treatment re-evaluation after two weeks establish a structured framework for therapy.

Recent Clinical Evidence

Clinivate: Recent Clinical Evidence

Assessment of Activity in Osteoarthritis

Clinical trials assessed the drug's activity in individuals diagnosed with mild-to-moderate knee osteoarthritis. The trials examined measures of pain and inflammation, using standardized assessment scales like the WOMAC index. The primary research focused on changes in pain scores after a 12-week treatment period.

Studies reviewed different dosages and their association with symptom changes. Research included comparative studies that analyzed observed effects on patient-reported pain levels. Findings from a pooled analysis of three Phase 3 trials showed results on the primary endpoint that varied slightly among the three individual trials.

Combination Therapy Investigations

Research investigated whether the combination of the study drug with a standard physiotherapy protocol was associated with changes in patient mobility and time to symptom changes. The study design for this investigation was an open-label trial lasting six months. It is not yet clear whether the addition of the study drug resulted in a different outcome compared to physiotherapy alone. Further, larger studies are exploring this question.

Safety and Tolerability Profile

Studies examined the drug's safety profile and activity over extended periods, up to one year, primarily focusing on the frequency of gastrointestinal and cardiovascular events. Studies noted certain findings regarding participants with severe liver or kidney disease. Common reported side effects included mild headache and temporary nausea. These events were generally self-limiting and did not frequently lead to discontinuation in the study population.

The studies observed symptom changes within a timeframe of 7–10 days in the trial data in some participants. Studies detailed the method used for drug administration.

Key Studies & References Integrated Summary of Efficacy for Drug X in Osteoarthritis: Pooled Analysis of Three Phase 3 Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Clinivate (FAQ)


Q: Does Clinivate cause weight gain or weight loss for most users?

Official information indicates that systemic exposure to the active ingredient may occur with prolonged or large-area use. This systemic exposure can lead to effects similar to Cushing's syndrome, which is sometimes associated with changes in body fat distribution. This is noted as a potential risk relating to systemic absorption.

Q: Do the side effects of Clinivate usually go away after a few weeks?

When first starting treatment, common local reactions, such as irritation, burning, or itching, may occur at the application site. Official patient information notes that these minor reactions may lessen or improve within the first few days of application as the skin adjusts to the treatment.

Q: Is Clinivate known to interact negatively with over-the-counter pain relievers like Advil (ibuprofen)?

Specific drug-drug interactions for topical Clinivate are not explicitly documented in the official labeling. However, its active ingredient belongs to the corticosteroid class, which, when used systemically, can be associated with an increased risk of gastrointestinal side effects when combined with NSAIDs like ibuprofen. Official regulatory documents emphasize caution regarding concurrent use with other corticosteroid-containing products to avoid additive exposure.

Q: What happens if I stop taking Clinivate suddenly?

Regulatory documents state that abrupt discontinuation of Clinivate, particularly after prolonged use, may lead to a rebound reaction. This reaction is reported as topical corticosteroid withdrawal. Official instructions advise that the drug should be discontinued once the symptoms of the condition are controlled.

Q: Do I have to take Clinivate for life, or is it only for a short time?

According to official guidelines, Clinivate is described as being for short-term use only. Treatment is generally intended to be stopped once the condition is controlled. If a condition does not improve within a two-week period, the treatment course is generally re-evaluated, according to official instructions.

Q: Is there a generic version of Clinivate available yet, or is it only brand name?

The active ingredient in Clinivate, Betamethasone Dipropionate, is available in generic forms that have been approved by regulatory bodies, such as the FDA. These generic preparations are manufactured by multiple companies in various forms, including creams and ointments.

Q: Are there any specific foods or drinks that must be avoided while taking Clinivate?

The official prescribing information for Clinivate topical preparations indicates that no explicit interactions with specific foods or drinks are documented.

Q: Can Clinivate cause problems with sleep, like insomnia or too much drowsiness?

Insomnia (difficulty sleeping) has been reported as an adverse reaction associated with the corticosteroid class of medicines. This effect is primarily linked to systemic exposure to the active ingredient, which is a potential risk with prolonged topical application.

Q: How does Clinivate affect fertility or pregnancy planning?

Regarding fertility, animal studies conducted on the active ingredient did not indicate impairment of male fertility. For pregnancy, the medicine is classified as Pregnancy Category C and is generally allowed only when the healthcare provider determines that the benefit outweighs the potential risk to the fetus.

Q: Can men and women use Clinivate to treat the same condition?

Official prescribing information indicates that the dosage and administration instructions provided for the authorized skin condition are the same for adult men and women.

Q: Is it possible to develop a dependency on Clinivate?

Continuous, prolonged use may lead to a biological limitation known as tachyphylaxis, which is a decrease in the drug's effectiveness over time. Additionally, a rebound reaction upon stopping the medicine, known as topical corticosteroid withdrawal, has been reported in literature after extended use.

Q: Will Clinivate interact with common vaccines, like the flu shot?

Corticosteroids possess immunosuppressive properties. Due to the possibility of the active ingredient being absorbed systemically, there is a possibility that a person's immune response to certain vaccines may be reduced.

Q: Why are there warnings about combining Clinivate with alcohol?

Official prescribing information for Clinivate indicates that no explicit interactions with alcohol are documented for topical preparations. Regulatory information indicates a lack of documented interaction between topical Clinivate and alcohol.

Q: Is the long-term safety of Clinivate supported by many years of research?

Studies evaluating the safety and tolerability profile of Clinivate have examined its effects for extended periods. Clinical trial data include investigations lasting up to one year, which specifically focus on systemic and local adverse reactions during treatment.

Q: Does Clinivate affect mental focus or ability to drive?

Systemic absorption of the active ingredient has the potential to cause effects on the central nervous system (CNS). These CNS effects are noted in official warnings as having the potential to influence a person's mood and cognition.

Q: Does Clinivate treat the underlying condition or just the symptoms?

The general purpose of Clinivate is described as alleviating the symptoms of inflammatory skin disorders. It achieves this by exerting a localized, powerful anti-inflammatory effect and immunosuppressive action, rather than addressing the core cause of the disease.

Q: Can Clinivate be used by children or teenagers?

Official labeling states that the medicine is not recommended for children 12 years of age and younger. If use in the pediatric population is authorized, treatment is often restricted to very short-term durations due to the increased risk of systemic effects in this age group.

Q: What are the signs that Clinivate might be interacting with another medicine?

The primary interaction concern is the potential for additive systemic exposure to corticosteroids. Signs of systemic toxicity resulting from this exposure, especially in children, can include effects like delayed weight gain, lower than normal plasma cortisol levels, or specific nervous system effects.

Q: Is the effectiveness of Clinivate reduced if it is taken with food?

Official prescribing information indicates that no explicit interactions related to food affecting the effectiveness of Clinivate topical preparations are documented.

Q: If I have a history of [Simulated contraindication], am I still eligible for Clinivate?

The medicine is contraindicated in patients with a known history of hypersensitivity to any of its components. Additionally, other conditions in a patient's medical history, such as severe liver or kidney disease, are noted in regulatory documents as risk factors for use.

Q: Is Clinivate a maintenance medicine or a rescue medicine?

Official guidelines describe Clinivate as being for short-term use only. Treatment is meant to be discontinued once the condition is under control, indicating it is not intended for long-term maintenance or chronic use.

Q: Is Clinivate considered a 'strong' medicine for [Condition it treats]?

Clinivate is officially classified as a high-potency corticosteroid topical preparation. This pharmacological classification defines the medicine's strength and intended role in managing inflammatory skin disorders.

Q: Can vitamins and herbal supplements interfere with how Clinivate works?

Official prescribing information indicates that no explicit interactions with herbal supplements or vitamins are documented for Clinivate topical preparations.

Q: Does research evidence suggest Clinivate is effective for people with mild symptoms?

Clinical trials assessed the drug's activity in individuals diagnosed with mild-to-moderate symptoms of knee osteoarthritis. This research examined measures of pain and inflammation, suggesting the drug was studied in patients with a range of symptom severity that includes mild presentation.

Q: Can Clinivate affect a person's mood or cause anxiety?

Systemic absorption of the active ingredient may potentially cause central nervous system (CNS) effects. These effects are noted in regulatory information as having the potential to influence a person's mood and cognition.

Q: How long does the effect of one dose of Clinivate last in the body?

The official dosing schedule for Clinivate is typically once daily or twice daily. This frequency is established to maintain the therapeutic effect and guides the recommended time between applications.

How should Clinivate be stored and disposed of?

How to Store and Dispose of Clinivate?

The storage and disposal instructions for Clinivate (Betamethasone Dipropionate topical preparation) are defined by regulatory labeling to maintain product stability and ensure safety.


Required Storage Conditions

Clinivate must be stored at controlled room temperature, specifically within the range of 20^circC to 25^circC (68^circF to 77^circF). Excursions are permitted between 15^circC and 30^circC (59^circF and 86^circF). The container must be kept tightly closed when not in use.

Child Safety and Disposal

It is a mandatory requirement to keep this medicine out of the reach of children.

For disposal of expired or unused medicine, do not flush the product down the toilet or pour it into a drain unless instructed otherwise. Disposal should be carried out as directed by a pharmacist or healthcare professional, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clinivate found in:

A-Z Index: